IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026
IGC Pharma completed enrollment in its Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer's dementia, with 168 participants randomized including planned over-enrollment. Final participant dosing is expected in early November, with topline results targeted for Q4 2026 after database lock and unblinding. The Data Safety Monitoring Committee has recommended the trial continue without modification at each periodic review, with no treatment-related serious adverse events identified to date.
Key figures
- Drug Name
- IGC-AD1
- Phase Of Trial
- Phase 2
- Female participants
- approximately 53%
- Final dosing timing
- early November 2026
- Topline results timing
- Q4 2026
- Average participant age
- approximately 78 years
- Participants randomized
- 168
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.